FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Christian Kollmannsberger

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Physiology

Drug Resistance, Neoplasm

Co-author Network

Publications

TOP 3
Jörg Thomas Hartmann; S Heeger; Christian Kollmannsberger; Frank Mayer; Marcus Schittenhelm; I Cascorbi; Carsten Bokemeyer
A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer.
Karin Oechsle; Christoph Oing; Lars Arne Berger; Carsten Bokemeyer; Christian Kollmannsberger; Frank Mayer; Friedemann Honecker
Bone metastases in germ cell tumor patients.
Karin Oechsle; Cornelius F Waller; I Boehlke; Carsten Bokemeyer; Jörg T Hartmann; Friedemann Honecker; Christian Kollmannsberger; Frank Mayer
Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Christian Kollmannsberger (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jörg Thomas Hartmann; S Heeger; Christian Kollmannsberger; Frank Mayer; Marcus Schittenhelm; I Cascorbi; Carsten Bokemeyer
A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer.
Investigational new drugs 2013;31(3):661-8.
2012: Karin Oechsle; Christoph Oing; Lars Arne Berger; Carsten Bokemeyer; Christian Kollmannsberger; Frank Mayer; Friedemann Honecker
Bone metastases in germ cell tumor patients.
Journal of cancer research and clinical oncology 2012;138(6):947-52.
2011: Karin Oechsle; Cornelius F Waller; I Boehlke; Carsten Bokemeyer; Jörg T Hartmann; Friedemann Honecker; Christian Kollmannsberger; Frank Mayer
Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors.
European urology 2011;60(4):850-5.
2011: Christian Kollmannsberger; Georg Bjarnason; Patrick Burnett; Patricia Creel; Mellar Davis; Nancy Dawson; Darren Feldman; Suzanne George; Jerome Hershman; Thomas Lechner; Amy Potter; Eric Raymond; Nathaniel Treister; Laura Wood; Shenhong Wu; Ronald Bukowski
Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.
The oncologist 2011;16(5):543-53.
2010: Christian Kollmannsberger; Siamak Daneshmand; Alan So; Kim N Chi; Nevin Murray; Christie Moore; Brandon Hayes-Lattin; Craig Nichols
Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(4):537-42.
2010: Karin Oechsle; Anja Lorch; Friedemann Honecker; Christian Kollmannsberger; Jörg T Hartmann; Ina Boehlke; Jörg Beyer; Carsten Bokemeyer
Patterns of relapse after chemotherapy in patients with high-risk non-seminomatous germ cell tumor.
Oncology 2010;78(1):47-53.
2008: Christian Kollmannsberger; F Honecker; Carsten Bokemeyer
Pharmacotherapy of relapsed metastatic testicular cancer.
Expert opinion on pharmacotherapy 2008;9(13):2259-72.
2008: Christian Kollmannsberger; Carsten Bokemeyer
Salvage chemotherapy after failure of first-line chemotherapy in patients with metastatic testicular cancer.
Current opinion in supportive and palliative care 2008;2(3):167-72.
2008: Carsten Bokemeyer; Karin Oechsle; Friedemann Honecker; Frank Mayer; Jörg Thomas Hartmann; C F Waller; I Böhlke; Christian Kollmannsberger
Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(3):448-53.
2007: Stefan Welz; Thomas Hehr; Christian Kollmannsberger; Carsten Bokemeyer; Claus Belka; Wilfried Budach
Renal toxicity of adjuvant chemoradiotherapy with cisplatin in gastric cancer.
International journal of radiation oncology, biology, physics 2007;69(5):1429-35.
2007: Jennifer J Knox; Sebastien J Hotte; Christian Kollmannsberger; Eric Winquist; Bryn Fisher; Elizabeth A Eisenhauer
Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161).
Investigational new drugs 2007;25(5):471-7.
2007: Andrew Robinson; Terry Bainbridge; Christian Kollmannsberger
A spermatocytic seminoma with rhabdomyosarcoma transformation and extensive metastases.
American journal of clinical oncology 2007;30(4):440-1.
2007: Anja Lorch; Christian Kollmannsberger; Jörg Thomas Hartmann; Bernd Metzner; Ingo G H Schmidt-Wolf; Wolfgang E Berdel; Florian Weissinger; Jan Schleicher; Gerlinde Egerer; Antje Haas; Rebekka Schirren; Jörg Beyer; Carsten Bokemeyer; Oliver Rick
Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(19):2778-84.
2007: Karin Oechsle; Friedemann Honecker; Christian Kollmannsberger; Oliver Rick; Victor Grünwald; Frank Mayer; Jörg Thomas Hartmann; Carsten Bokemeyer
An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors.
Anti-cancer drugs 2007;18(3):273-6.
2006: Christian Kollmannsberger; Friedemann Honecker; Carsten Bokemeyer
Treatment of germ cell tumors--update 2006.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17 Suppl 10():x31-5.
2006: Christian Kollmannsberger; Marcus Schittenhelm; Friedemann Honecker; J Tillner; D Weber; Karin Oechsle; Lothar Kanz; Carsten Bokemeyer
A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(6):1007-13.
2006: Heather L McArthur; Bakul I Dalal; Christian Kollmannsberger
Intravascular hemolysis as a complication of clostridium perfringens sepsis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(15):2387-8.
2006: Christian Kollmannsberger; Craig Nichols; Carsten Bokemeyer
Recent advances in management of patients with platinum-refractory testicular germ cell tumors.
Cancer 2006;106(6):1217-26.
2006: Jorg Michels; Trina Montemurro; Nevin Murray; Christian Kollmannsberger; Kim Nguyen Chi
First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?
Cancer 2006;106(5):1041-6.
2005: Abdulwahab J Al-Tourah; Nevin Murray; Chris Coppin; Christian Kollmannsberger; Ada Man; Kim N Chi
Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.
The Journal of urology 2005;174(6):2209-13, discussion 2213.
2005: Christian Kollmannsberger; W Budach; M Stahl; Norbert Schleucher; Thomas Hehr; Hansjochen Wilke; Jan Schleicher; Udo Vanhoefer; Ekkehard C Jehle; Karin Oechsle; Tanja Trarbach; I Boehlke; Lothar Kanz; Jörg Thomas Hartmann; Carsten Bokemeyer
Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(8):1326-33.
2005: Bakul I Dalal; Christian Kollmannsberger
Drug-induced haemolysis and methaemoglobinaemia in glucose 6-phosphate dehydrogenase deficiency.
British journal of haematology 2005;129(3):291.
2005: Jan Wierecky; Christian Kollmannsberger; I Boehlke; Markus Kuczyk; Jan Schleicher; Norbert Schleucher; Bernd Metzner; Lothar Kanz; Jörg Thomas Hartmann; Carsten Bokemeyer
Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer.
Journal of cancer research and clinical oncology 2005;131(4):255-60.
2004: Carsten Bokemeyer; Christian Kollmannsberger; Sally P Stenning; Jörg Thomas Hartmann; Alan Horwich; C Clemm; Arthur Gerl; Christoph Meisner; C-P Rückerl; Hans-J Schmoll; Lothar Kanz; T Oliver
Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials.
British journal of cancer 2004;91(4):683-7.
2004: Anna C Pfannenberg; Karin Oechsle; Carsten Bokemeyer; Christian Kollmannsberger; Bernhard M Dohmen; Roland Bares; Jörg Thomas Hartmann; Reinhard Vonthein; Claus D Claussen
The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors--prospects for management.
World journal of urology 2004;22(2):132-9.
2004: Markus A Kuczyk; Carsten Bokemeyer; Christian Kollmannsberger; Stefan Corvin; Aristotelis G Anastasiadis; Stefan Machtens; Axel S Merseburger; Gerd Wegener; A Stenze; Jörg Thomas Hartmann; Udo Jonas
Late relapse after treatment for nonseminomatous testicular germ cell tumors according to a single center-based experience.
World journal of urology 2004;22(1):55-9.
2004: Oliver Rick; Christian Kollmannsberger; Jörg Thomas Hartmann; T Braun; Wolfgang Siegert; Carsten Bokemeyer; Jörg Beyer
The role of high-dose chemotherapy in relapsed germ cell tumors.
World journal of urology 2004;22(1):25-32.
2004: Anna C Pfannenberg; Karin Oechsle; Christian Kollmannsberger; Bernhard M Dohmen; Carsten Bokemeyer; Roland Bares; R Vontheim; Claus D Claussen
[Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].
RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin 2004;176(1):76-84.
2004: Christian Kollmannsberger; Jörg Beyer; R Liersch; P Schoeffski; Bernd Metzner; Jörg Thomas Hartmann; Oliver Rick; K Stengele; K Hohloch; C Spott; Lothar Kanz; Carsten Bokemeyer
Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(1):108-14.
2003: Axel S Merseburger; Gerd Wegener; Marcus Horstmann; M Oelke; Andreas Zumbrägel; Carsten Bokemeyer; Christian Kollmannsberger; Udo Jonas; Arnulf Stenzl; Markus Kuczyk
[Impact of tumor size on long-term survival of patients with organ-confined renal cell cancer].
Aktuelle Urologie 2003;34(7):469-74.
2003: Hans-J Schmoll; Christian Kollmannsberger; Bernd Metzner; Jörg Thomas Hartmann; Norbert Schleucher; Patrick Schöffski; Jan Schleicher; Oliver Rick; Jörg Beyer; Dieter K Hossfeld; Lothar Kanz; Wolfgang E Berdel; Reinhard Andreesen; Carsten Bokemeyer
Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(22):4083-91.
2003: Oliver Rick; Christian Kollmannsberger; Jörg Beyer; Carsten Bokemeyer
Current aspects of high-dose chemotherapy in germ-cell tumors.
Critical reviews in oncology/hematology 2003;47(3):237-48.
2003: Carsten Bokemeyer; Norbert Schleucher; Bernd Metzner; M Thomas; Oliver Rick; Hans-J Schmoll; Christian Kollmannsberger; I Boehlke; Lothar Kanz; Jörg Thomas Hartmann
First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial.
British journal of cancer 2003;89(1):29-35.
2003: Christian Kollmannsberger; Norbert Schleucher; Oliver Rick; Bernd Metzner; Jörg Thomas Hartmann; Patrick Schöffski; Jörg Beyer; Jochen Casper; M Sosada; Hans-J Schmoll; I Böhlke; Christoph Meisner; Lothar Kanz; Carsten Bokemeyer
Analysis of salvage treatments for germ cell cancer patients who have relapsed after primary high-dose chemotherapy plus autologous stem cell support.
European journal of cancer (Oxford, England : 1990) 2003;39(6):775-82.
2003: Markus Kuczyk; Torsten Münch; Carsten Bokemeyer; Axel S Merseburger; AE Wefer; Christian Kollmannsberger; M Kondoh; Gerd Wegener; Udo Jonas; Arnulf Stenzl
[Is adrenalectomy an indispensable part of nephrectomy? Results of a multivariate statistical analysis].
Der Urologe. Ausg. A 2003;42(3):366-73.
2003: Katja Ott; Andreas Sendler; Karen Becker; Hans-Joachim Dittler; Hermann Helmberger; Raymonde Busch; Christian Kollmannsberger; J Rüdiger Siewert; Ulrich Fink
Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2003;6(3):159-67.
2002: Christian Kollmannsberger; Oliver Rick; H Klaproth; T Kubin; H G Sayer; M Hentrich; M Welslau; Frank Mayer; Markus Kuczyk; C Spott; Lothar Kanz; Carsten Bokemeyer
Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group.
British journal of cancer 2002;87(7):729-32.
2002: Markus Kuczyk; Stefan Machtens; C Bokemeyer; Christian Kollmannsberger; J Hartmann; M Kondoh; Axel S Merseburger; Udo Jonas
Surgical bladder preserving strategies in the treatment of muscle-invasive bladder cancer.
World journal of urology 2002;20(3):183-9.
2002: Christian Kollmannsberger; Frank Mayer; Harald Pressler; S Koch; Lothar Kanz; J W Oosterhuis; Leendert H J Looijenga; Carsten Bokemeyer
Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer.
Cancer 2002;95(2):301-8.
2002: Friedemann Honecker; Christian Kollmannsberger; Detlef Quietzsch; Caroline Haag; M Schroeder; C Spott; Jörg Thomas Hartmann; W Baronius; V Hempel; Lothar Kanz; Carsten Bokemeyer
Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
Anti-cancer drugs 2002;13(5):497-503.
2002: Christian Kollmannsberger; Karin Oechsle; Bernhard M Dohmen; Anna C Pfannenberg; Roland Bares; Claus D Claussen; Lothar Kanz; Carsten Bokemeyer
Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
Cancer 2002;94(9):2353-62.
2002: Christian Kollmannsberger; Oliver Rick; Hans Günter Derigs; Norbert Schleucher; Patrick Schöffski; Jörg Beyer; R Schoch; H G Sayer; Arthur Gerl; Markus Kuczyk; C Spott; Lothar Kanz; Carsten Bokemeyer
Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2031-7.
2002: Markus Kuczyk; Torsten Münch; Stefan Machtens; Carsten Bokemeyer; AE Wefer; J Hartmann; Christian Kollmannsberger; M Kondo; Udo Jonas
The need for routine adrenalectomy during surgical treatment for renal cell cancer: the Hannover experience.
BJU international 2002;89(6):517-22.
2002: Carsten Bokemeyer; Christian Kollmannsberger; Karin Oechsle; Bernhard M Dohmen; Anna C Pfannenberg; Claus D Claussen; Roland Bares; Lothar Kanz
Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET.
British journal of cancer 2002;86(4):506-11.
2001: Markus A Kuczyk; Carsten Bokemeyer; J Hartmann; J Schubach; C Walter; Stefan Machtens; R Knuchel; Christian Kollmannsberger; Udo Jonas; Jürgen Serth
Predictive value of altered p27Kip1 and p21WAF/Cip1 protein expression for the clinical prognosis of patients with localized prostate cancer.
Oncology reports 2001;8(6):1401-7.
2001: Helmut Dittmann; M Sokler; Christian Kollmannsberger; Bernhard M Dohmen; C Baumann; A Kopp; Roland Bares; C D Claussen; L Kanz; Carsten Bokemeyer
Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma.
Oncology reports 2001;8(6):1393-9.
2001: Stefan Machtens; Jürgen Serth; Carsten Bokemeyer; W Bathke; A Minssen; Christian Kollmannsberger; J Hartmann; R Knüchel; M Kondo; Udo Jonas; Markus Kuczyk
Expression of the p53 and Maspin protein in primary prostate cancer: correlation with clinical features.
International journal of cancer. Journal international du cancer 2001;95(5):337-42.
2001: Christian Kollmannsberger; Frank Mayer; Markus Kuczyk; Lothar Kanz; Carsten Bokemeyer
Treatment of patients with metastatic germ cell tumors relapsing after high-dose chemotherapy.
World journal of urology 2001;19(2):120-5.
2000: Christian Kollmannsberger; Craig Nichols; Christoph Meisner; Frank Mayer; Lothar Kanz; Carsten Bokemeyer
Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(9):1115-20.
2000: Christian Kollmannsberger; Arthur Gerl; Norbert Schleucher; Jörg Beyer; Markus Kuczyk; Oliver Rick; Jochen Casper; M Sosada; C Rie; Lothar Kanz; Carsten Bokemeyer
Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer.
Anti-cancer drugs 2000;11(7):535-9.
2000: Christian Kollmannsberger; Detlef Quietzsch; Caroline Haag; T Lingenfelser; M Schroeder; Jörg Thomas Hartmann; W Baronius; V Hempel; Michael Clemens; Lothar Kanz; Carsten Bokemeyer
A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.
British journal of cancer 2000;83(4):458-62.
2000: Christian Kollmannsberger; Craig Nichols; D D; Jörg Thomas Hartmann; Norbert Schleucher; Jörg Beyer; P Schöfski; Günter Derigs; U Rüther; I Böhlke; Hans-J Schmoll; Lothar Kanz; Carsten Bokemeyer
First-line high-dose chemotherapy +/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(5):553-9.
2000: Carsten Bokemeyer; Christian Kollmannsberger; Jörg Thomas Hartmann; Lothar Kanz
Follow up after primary treatment: curable diseases treated non-surgically.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11 Suppl 3():73-8.
1999: Jörg Thomas Hartmann; Christian Kollmannsberger; Lothar Kanz; Carsten Bokemeyer
Platinum organ toxicity and possible prevention in patients with testicular cancer.
International journal of cancer. Journal international du cancer 1999;83(6):866-9.
1999: Christian Kollmannsberger; Jörg Thomas Hartmann; Lothar Kanz; Carsten Bokemeyer
Therapy-related malignancies following treatment of germ cell cancer.
International journal of cancer. Journal international du cancer 1999;83(6):860-3.
1999: Carsten Bokemeyer; Christian Kollmannsberger; Andreas Harstrick; Jörg Beyer; Arthur Gerl; Jochen Casper; Bernd Metzner; Jörg Thomas Hartmann; Hans-J Schmoll; Lothar Kanz
Treatment of patients with cisplatin-refractory testicular germ-cell cancer. German Testicular Cancer Study Group (GTCSG).
International journal of cancer. Journal international du cancer 1999;83(6):848-51.
1999: Christian Kollmannsberger; M Kuzcyk; Frank Mayer; Jörg Thomas Hartmann; Lothar Kanz; Carsten Bokemeyer
Late toxicity following curative treatment of testicular cancer.
Seminars in surgical oncology 1999;17(4):275-81.
1999: Christian Kollmannsberger; Harald Pressler; Frank Mayer; Lothar Kanz; Carsten Bokemeyer
Cisplatin-refractory, HER2/neu-expressing germ-cell cancer: induction of remission by the monoclonal antibody Trastuzumab.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(11):1393-4.
1999: Carsten Bokemeyer; Christian Kollmannsberger; Christoph Meisner; Andreas Harstrick; Jörg Beyer; Bernd Metzner; Jörg Thomas Hartmann; Hans-J Schmoll; Lawrence Einhorn; Lothar Kanz; Craig Nichols
First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3450-6.
1999: Jörg Thomas Hartmann; Markus A Kuczyk; Christian Kollmannsberger; Lothar Kanz; Carsten Bokemeyer
Future prospects in the chemotherapy of metastatic nonseminomatous testicular germ-cell cancer.
World journal of urology 1999;17(5):324-33.
1999: Jörg Thomas Hartmann; Detlef Quietzsch; Thomas Daikeler; Christian Kollmannsberger; Frank Mayer; Lothar Kanz; Carsten Bokemeyer
Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer.
Anti-cancer drugs 1999;10(8):729-33.
1999: Carsten Bokemeyer; Jörg Thomas Hartmann; Christian Kollmannsberger; Frank Mayer; Lothar Kanz
UFT/calcium folinate plus weekly paclitaxel for solid tumors.
Oncology (Williston Park, N.Y.) 1999;13(7 Suppl 3):106-11.
1999: Christian Kollmannsberger; W Brugger; Jörg Thomas Hartmann; Franz Maurer; P Böhm; Lothar Kanz; Carsten Bokemeyer
Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma.
Anti-cancer drugs 1999;10(5):453-6.
1999: Jörg Thomas Hartmann; C Albrecht; Hans-J Schmoll; Markus A Kuczyk; Christian Kollmannsberger; Carsten Bokemeyer
Long-term effects on sexual function and fertility after treatment of testicular cancer.
British journal of cancer 1999;80(5-6):801-7.
1999: Christian Kollmannsberger; K Mross; Andreas Jakob; Lothar Kanz; Carsten Bokemeyer
Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience.
Oncology 1999;56(1):1-12.
1998: Andreas Jakob; Christian Kollmannsberger; Lothar Kanz; Carsten Bokemeyer
[Late toxicity after chemotherapy of malignant testicular tumors].
Der Urologe. Ausg. A 1998;37(6):635-47.
1998: Christian Kollmannsberger; Jörg Beyer; Jean Pierre Droz; Andreas Harstrick; Jörg Thomas Hartmann; Pierre Biron; Aude Fléchon; Patrick Schöffski; Markus Kuczyk; Hans-J Schmoll; Lothar Kanz; Carsten Bokemeyer
Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(10):3386-91.
1998: Jörg Thomas Hartmann; Andreas Harstrick; Thomas Daikeler; Christian Kollmannsberger; C Müller; S Seeber; Lothar Kanz; Carsten Bokemeyer
Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer.
Anti-cancer drugs 1998;9(5):427-31.
1998: Christian Kollmannsberger; H D Peters; U Fink
Chemotherapy in advanced pancreatic adenocarcinoma.
Cancer treatment reviews 1998;24(2):133-56.
1998: Carsten Bokemeyer; C C Berger; Jörg Thomas Hartmann; Christian Kollmannsberger; Hans-J Schmoll; Markus A Kuczyk; Lothar Kanz
Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.
British journal of cancer 1998;77(8):1355-62.
1998: Carsten Bokemeyer; Jörg Thomas Hartmann; Markus A Kuczyk; M C Truss; Christian Kollmannsberger; Jörg Beyer; Udo Jonas; Lothar Kanz
Recent strategies for the use of paclitaxel in the treatment of urological malignancies.
World journal of urology 1998;16(2):155-62.
1998: Christian Kollmannsberger; Jörg Thomas Hartmann; Lothar Kanz; Carsten Bokemeyer
Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies.
Journal of cancer research and clinical oncology 1998;124(3-4):207-14.
1997: Carsten Bokemeyer; C S Lampe; M R Clemens; Jörg Thomas Hartmann; Detlef Quietzsch; L Forkmann; Christian Kollmannsberger; Lothar Kanz
A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer.
Anti-cancer drugs 1997;8(4):396-9.